Search Protocols under revision. Back New search Go to resultsDiseaseMain groupSolid TumorsProtocol groupThoracic TumorsDiseaseBladder CancerBreast CancerHepatocellular CarcinomaLung Carcinoma, Non-Small CellLung Carcinoma, Small CellSubgrouptripel negativeICD10C22.0C34.-C50.-C67.-MeSHBreast NeoplasmsCarcinoma, HepatocellularCarcinoma, Non-Small-Cell LungCarcinoma, Transitional CellLiver NeoplasmsSmall Cell Lung CarcinomaUrinary Bladder NeoplasmsSequenceChemotherapyChemo-substanceAtezolizumabChemo-substanceAtezolizumabChemo-substanceAtezolizumabChemo-substanceAtezolizumabNo. Substances1 RadiotherapySupportive therapySupportive substanceSupportive substanceSupportive substanceSupportive substanceNo. SubstancesProtocol classificationTherapy classificationalternativeIntensityStandard doseTherapy indicationseveral possibleTherapy phaseTherapy intentioncurative or palliativeRisksEmetogenicity (MASCC/ESMO)Hyperglycemia only studiesPublicationAuthorBurotto MDiseaseNSCLC, lokal fortgeschritten oder metastasiert, ECOG 0-1OriginCentro de Investigacion, Clinica Bradford Hill, Santiago, Chile, IMscin001 trialProtocols in Revision 1 protocol foundAtezolizumab 1875, single dose subcutaneous (PID3181 V1.0)
